Bitter I

Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.

5 papers · ORCID

ArticleKetamine

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticleKetamine

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

Reif A, Anıl Yağcıoğlu AE, Bitter I +11

Europe PMC2026
ArticleKetamine

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticleKetamine

Top-line Results from ESCAPE-LTE: An Open-Label Extension Study to Assess Long-term Safety of Esketamine Nasal Spray in Treatment Resistant Depression

Godinov Y, Fu D, von Holt C +10

Europe PMC2025
ArticleKetamine

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

McIntyre RS, Bitter I, Buyze J +9

Europe PMC2024